Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors.
We describe four patients with galactorrhoea as an isolated endocrine abnormality after use of protease inhibitors (PIs) as part of both highly active antiretroviral therapy (HAART) and postexposure prophylaxis (PEP). This reaction may be a direct effect of PIs or may be indirectly mediated by the effect of PIs on the cytochrome P450 system, thus potentiating the dopamine antagonist effects of other drugs.
Hutchinson
J
J
Murphy
M
M
Harries
R
R
Skinner
C J
CJ
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D005260:Female; D005687:Galactorrhea / Q000139:chemically induced*; D015658:HIV Infections / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D015497:HIV-1; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced*; D016602:Needlestick Injuries; D011480:Protease Inhibitors / Q000009:adverse effects*; D011902:Rape
D019380:Anti-HIV Agents; D011480:Protease Inhibitors; D003577:Cytochrome P-450 Enzyme System